In conclusion, ALL cells with miR-182 promoter hypermethylation, which present low expression of miR-182 and high protein level of BCL2, are sensitive to DAC + Ven cotreatment, suggesting that DAC + Ven has further clinical application for ALL patients with miR-182 promoter hypermethylation. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.